disease-free survival


Also found in: Acronyms.
The amount of time that a person with a disease—usually understood to mean cancer—lives without known recurrence. Disease-free survival is a major clinical parameter used to evaluate the efficacy of a particular therapy, which is usually measured in ‘units’ of 1 or 5 years

disease-free survival

Oncology The time that a person with a disease lives without known recurrence; DFS is major clinical parameter used to evaluate the efficacy of a particular therapy, which is usually measured in 'units' of 1 or 5 yrs. See Cure, Remission.
References in periodicals archive ?
However, the trial still reached 84% power to detect noninferiority of the primary outcome (disease-free survival) with minimally invasive surgery, which was not found, they noted.
In this article, we describe our study to determine if adjunctive RT had an effect on disease-free survival in patients with oral SCC who were found to have close surgical margins after tumor resection.
In the present study, overall survival and disease-free survival were calculated at 1 year after treatment as the duration of the present study was less (approximately 2 years).
Results showed that patients who had three or four of the altered genes had worse disease-free survival (the time between surgery and when cancer returns), and overall survival (from surgery to death), compared to patients with a single or two altered genes.
There were no significant differences in disease-free survival, recurrence and location of recurrence, or overall survival in 760 patients treated by total laparoscopic hysterectomy or total abdominal hysterectomy.
A multivariate analysis showed that vitamin D level was associated with overall survival (OS) (hazard ratio, 1.02 per unit decrease of vitamin D; P = .005), melanoma-specific survival (MSS) (HR, 1.02; P = .048), and disease-free survival (DFS) (HR, 1.02; P = .043).
However, many of those patients will relapse and only about 30 to 50 percent will achieve long-term, disease-free survival lasting more than three years.
The combination group also had better disease-free survival of 10.4 years vs.
Disease-free survival rates in DP group in one and two years were 76.5% and 50.47%, respectively, whereas in GP group were 77.8% and 49.52%, respectively.
The trial showed that following intensive myeloablative conditioning, stem cell transplantation from an identical sibling donor processed using the CliniMACS CD34 Reagent System as the sole means of GVHD prophylaxis leads to a low incidence of chronic GVHD (19 percent at two years after transplantation) without negatively affecting relapse, engraftment, overall survival or disease-free survival (Pasquini et al.
Overall median disease-free survival was 14 months and overall median survival was 27 months.